Home > Insider Trading > Filing (0001104659-21-130026)

Filing Details

Accession Number:: 0001104659-21-130026
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-10-26 17:01:35
Reporting Period:: 2021-10-26

Accepted Time:: 2021-10-26 17:01:35
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1840233	Xilio Therapeutics Inc.	XLO	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1708269	Atlas Venture Fund Xi, L.p.	300 Technology Square, 8Th Floor Cambridge MA 02139		No	No	Yes	No
1759241	Atlas Venture Opportunity Fund I, L.p.	400 Technology Square, 10Th Floor Cambridge MA 02139		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-10-26	1,372,998	$0.00	1,399,313	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-10-26	624,089	$0.00	2,023,402	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-10-26	548,442	$0.00	548,442	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-10-26	187,500	$16.00	735,942	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A1 Preferred Stock	Disposition	2021-10-26	13,043,477	$0.00	1,372,998	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-10-26	5,928,852	$0.00	624,089	$0.00
Common Stock	Series C Preferred Stock	Disposition	2021-10-26	5,210,204	$0.00	548,442	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The Series A1 Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series A1 Preferred Stock had no expiration date.
The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.
The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.
The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date.
The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.